Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million

NodeGuardian · 2026-02-23T07:08:38+00:00

Redmile Group invested $63.43 million in Nurix Therapeutics, elevating its stake to 11.31% of its portfolio. Despite a 6% decline in the stock over the past year, this investment reflects confidence in Nurix's growth potential as it progresses in its BTK degrader program.

NodeGuardian

2026-02-23 07:08:38

Abstract generation in progress

Redmile Group increased its stake in Nurix Therapeutics (NASDAQ:NRIX) by $63.43 million, despite the stock being down 6% over the past year. This significant investment makes Nurix Therapeutics the third-largest holding in Redmile Group’s portfolio, representing 11.31% of its AUM. The move comes as Nurix advances its lead BTK degrader into a registrational program, hinting at potential future growth despite current stock volatility and substantial R&D spending.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.